Found 12 results
Author Keyword Title [ Type(Desc)] Year
Filters: Author is Bradley J Monk  [Clear All Filters]
Journal Article
S. Sagae, Monk, B. J., Pujade-Lauraine, E., Gaffney, D. K., Narayan, K., Ryu, S. Young, McCormack, M., Plante, M., Casado, A., Reuss, A., Chávez-Blanco, A., Kitchener, H. C., Nam, B. - H., Jhingran, A., Temkin, S., Mileshkin, L. R., Berns, E. M. J. J., Scholl, S., Doll, C., Abu-Rustum, N. R., Lecuru, F., and Small, W., Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future., Int J Gynecol Cancer, vol. 26, no. 1, p. 207, 2016.
R. T. Penson, Huang, H. Q., Wenzel, L. B., Monk, B. J., Stockman, S., Long, H. J., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J. A., Leitao, M. M., Method, M., Michael, H., and Tewari, K. S., Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)., Lancet Oncol, vol. 16, no. 3, pp. 301-11, 2015.
T. J. Herzog, Vermorken, J. B., Pujade-Lauraine, E., Provencher, D. M., Jagiello-Gruszfeld, A., Kong, B., Boman, K., Park, Y. Choi, Parekh, T., Lebedinsky, C., Gómez, J., and Monk, B. J., Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study., Gynecol Oncol, vol. 122, no. 2, pp. 350-5, 2011.
H. Fujiwara, Yokota, H., Monk, B. J., Treilleux, I., Devouassoux-Shisheboran, M., Davis, A., Kim, J. - W., Mahner, S., Stany, M., Pignata, S., Ray-Coquard, I., and Fujiwara, K., Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S96-101, 2014.
K. S. Tewari, Sill, M. W., Long, H. J., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., Michael, H. E., and Monk, B. J., Improved survival with bevacizumab in advanced cervical cancer., N Engl J Med, vol. 370, no. 8, pp. 734-43, 2014.
A. du Bois, Floquet, A., Kim, J. - W., Rau, J., Del Campo, J. M., Friedlander, M. Leonard, Pignata, S., Fujiwara, K., Vergote, I. B., Colombo, N., Mirza, M. R., Monk, B. J., Kimmig, R., Ray-Coquard, I., Zang, R., Diaz-Padilla, I., Baumann, K. H., Mouret-Reynier, M. - A., Kim, J. - H., Kurzeder, C., Lesoin, A., Vasey, P. A., Marth, C., Canzler, U., Scambia, G., Shimada, M., Calvert, P., Pujade-Lauraine, E., Kim, B. - G., Herzog, T. J., Mitrica, I., Schade-Brittinger, C., Wang, Q., Crescenzo, R. J., and Harter, P., Incorporation of pazopanib in maintenance therapy of ovarian cancer., J Clin Oncol, vol. 32, no. 30, p. 3382, 2014.
B. J. Monk, Pujade-Lauraine, E., and Burger, R. A., Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease., Ann Oncol, vol. 24 Suppl 10, p. x58, 2013.
M. Markman, Liu, P. Y., Wilczynski, S. P., Monk, B. J., Copeland, L., Alvarez, R. D., Jiang, C., Alberts, D. S., Group, S. Oncology, and Group, G. Oncology, Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial, J Clin Oncol, vol. 21, pp. 2460-5, 2003.
L. M. Randall, Sill, M. W., Burger, R. A., Monk, B. J., Buening, B., and Sorosky, J. I., Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial, Gynecol Oncol, vol. 124, pp. 563-8, 2012.
A. Floquet, Vergote, I. B., Colombo, N., Fiane, B., Monk, B. J., Reinthaller, A., Calvert, P., Herzog, T. J., Meier, W., Kim, J. - W., Del Campo, J. M., Friedlander, M. Leonard, Pisano, C., Isonishi, S., Crescenzo, R. J., Barrett, C., Wang, K., Mitrica, I., and du Bois, A., Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial., Gynecol Oncol, vol. 136, no. 1, p. 42, 2015.
M. Leonard Friedlander, Rau, J., Lee, C. Khoon, Meier, W., Lesoin, A., Kim, J. - W., Poveda, A. M., Buck, M., Scambia, G., Shimada, M., Hilpert, F., King, M. Trudy, Debruyne, P., Bologna, A., Malander, S., Monk, B. J., Petru, E., Calvert, P., Herzog, T. J., Barrett, C., and A Bois, du, Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial., Ann Oncol, vol. 29, no. 3, pp. 737-743, 2018.
J. K. Chan, Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., Huh, W. K., O'Malley, D. M., Boente, M. P., Michael, H., and Monk, B. J., Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer., N Engl J Med, vol. 374, no. 8, p. 748, 2016.